Industrial Biotech Flourish News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Moji Karimi, CEO, Cemvita Factory
Special to The Digest
1. Product or platform?
A) Product: develop the microbe, build the plant, and sell the product. The end molecule is the revenue source
B) Platform: develop the microbe and commercialize it through partnerships. The microbe is the revenue source
2. What molecules to develop?
A) Specialty: high value, low volume
B) Commodity: high volume, low value
3. What market to serve?
A) Target verticals with SynBio capability or familiarity
B) Target verticals that may not have SynBio capability or familiarity
These answers land a company somewhere on this spectrum:
It’s not that one quadrant is better than the other. It’s just about where the focus is for a given company and how they are optimizing for technology and market risk vs. their long-term ambitions for scaling up the company. So far, most of the de-risking and existing data comes from Q3, the product focus and specialty mol ....

Moji Karimi , Ginkgo Bioworks , Biofuel Digest , Industrial Biotech Flourish , மோஜி கரிமி , உயிரி எரிபொருள் ஜீரணிக்கவும் ,